Investor Home

Corporate Profile

argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.

argenx is listed on Euronext Brussels and on the NASDAQ; all with the ticker symbol ARGX.

We have a strong investor base, with a long term commitment to the biotech industry. Whether you are a current investor in argenx or are evaluating argenx as a potential investment opportunity, we welcome you to contact us should you have any additional questions after reviewing our website.

Stock Information

Financial Calendar
Q3 2019 results
Wolfe Research Conference
Keith Woods, COO